Dr. Lal PathLabs (LALPATHLAB) investor relations material

Executive summary

• Q2 FY27 consolidated revenue rose 19.6% YoY to INR 8,739m; EBITDA increased 25.1% to INR 280 crore and profit rose 27.5% to INR 1,939m.

• H1 FY27 consolidated revenue reached INR 16,716m, up 19.4%; the board approved a second interim dividend of INR 5/share and up to INR 49.5 crore of further investment in Dr. Lal PathLabs FZCO.

Financial highlights

• Consolidated Q2 revenue from operations was INR 8,739m versus INR 7,306m YoY; PBT was INR 2,605m versus INR 2,036m.

• Consolidated Q2 profit was INR 1,939m versus INR 1,522m YoY; H1 revenue was INR 16,716m and profit INR 3,644m, versus INR 2,862m profit in the prior year.

• Q2 EBITDA was INR 280 crore, up 25.1%; H1 EBITDA was INR 528 crore, up 26.7%.

• Standalone Q2 revenue was INR 8,321m and profit INR 1,797m; H1 revenue was INR 15,965m and profit INR 3,456m.

• Q2 PBT grew 28.1%; H1 PBT reached INR 489 crore, up 27.2%.

Outlook and guidance

• FY27 revenue growth is expected in the high teens, with full-year EBITDA performance expected to be slightly better than FY26; longer-term organic revenue growth expectation is mid-teens.

• Longer-term organic growth is supported by patient volume and realization growth expectations of 6%-7% each; management aims to balance growth investment with profitability and improve network productivity.

• No near-term price increase is planned; timing will be reassessed over the next one or two quarters based on cost pressure and market pricing benchmarks.

• Higher-than-expected H1 margins may support increased H2 investment; Sovaaka, radiology and international initiatives are longer-term contributors, not expected to be significant in the next two to three years.

• Growth priorities include scientific leadership, patient experience, AI, new revenue models, operational excellence, M&A and international business; opportunities include preventive and precision medicine and specialized testing.